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Introduction: Although atherogenesis is clearly entwined with systemic inﬂ  ammation, the 
risk-predictive relationship between preclinical and overt cardiovascular disease (CVD) and 
systemic white blood cell (WBC) subtypes remains unclear. Implication of an association would 
greatly facilitate cardiac risk prediction, assessment and monitoring.
Methods: 1383 asymptomatic individuals (795 men, 588 women) attending for executive 
health screening were examined clinically as well as with phlebotomy and exercise stress test-
ing to determine their ten-year risk of developing overt cardiovascular disease (as estimated 
by both Framingham and SCORE calculations). The signiﬁ  cance of their association with 
overall WBC and subtypes were determined using both univariate and multiple regression 
modeling.
Results: Of all WBC subtypes, monocyte count was found to have the strongest, independent 
relationship with overall CVD risk by backwards linear regression modeling (Framingham: 
β = 0.057; p = 0.03; SCORE: β = 0.128; p =  0.0005). Independent associations with BMI 
(β = 5.214; p =  0.0005), waist circumference (β = 21.866; p =  0.0005), systolic blood 
pressure (β = 10.738; p = 0.003), HDL cholesterol (β = −0.639; p =  0.0005) and triglyceride 
concentrations (β = 0.787; p =  0.0005) were also evident. Overall WBC along with neutrophils, 
lymphocytes and basophil subfractions were variably (but less strongly) associated with such 
dependents and outcome measures.
Conclusions: In conclusion, monocyte count, a simple inexpensive test, may provide useful 
predictive cardiovascular risk information in asymptomatic individuals to inform and guide 
attempts at interrupting CVD development at a preclinical stage.
Keywords: leukocyte, white cell count, monocyte, cardiovascular risk, asymptomatic 
population
Introduction
Inﬂ  ammation plays a key role in the pathogenesis of atherosclerosis and in the 
development of clinically apparent cardiovascular disease (CVD) (Yarnell et al 1991; 
Ross 1993, 1999; Libby 1995; Falk et al 1995; Tracey 1998; Ridker 1998). Elevated 
levels of systemic inﬂ  ammatory markers have been shown to be associated with an 
increased risk of symptomatic coronary heart disease (CHD) (Folsom et al 1995, 1997; 
Danesh et al 2000), while total white blood cell (WBC) count has itself been shown 
to be an independent risk factor for both CHD development (Danesh et al 1998) and 
CVD-related morbidity and mortality (Kannel et al 1992; Horne et al 2005). Although 
a role as a biomarker of cardiovascular risk has been suggested for total WBC (Grimm 
et al 1985; Kuller et al 1996; Pepys and Berger 2001; Pearson et al 2003), the relative 
ability of speciﬁ  c WBC subtypes to predict cardiovascular risk in asymptomatic 
individuals remains largely unexamined. Such an analysis may provide greater insight 
into the natural history of actual cardiovascular risk. While neutrophil levels have Vascular Health and Risk Management 2008:4(1) 178
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proven useful in reﬂ  ecting overt ischemic events post-hoc, 
a preclinical indicator of impending atherosclerotic crisis 
could provide greater therapeutic opportunity.
Thus, in this prospective observational study, the predic-
tive ability of total and speciﬁ  c WBC subtypes on predicted 
cardiovascular risk in a cohort of patients without preexisting 
symptomatic CVD was evaluated both alone and in compari-
son to conventional risk factors.
Methods
Study sample
The study population consisted of consecutive asymptomatic 
males and females without prior history of clinically apparent 
cardiovascular disease and aged between 33 and 75 years who 
attended an executive cardiovascular health examination in 
the Department of Preventative Medicine, Blackrock Clinic, 
Dublin, Ireland, between December 2003 and March 2005. All 
enrolled participants were self-referred and underwent their 
evaluation by a physician in an outpatient setting. The study 
was approved by the Ethics Committee of Blackrock Clinic.
Initially, all participants completed a detailed health 
questionnaire to confirm the presence or absence of 
symptoms of heart disease (chest pain, dyspnoea, palpitations 
at rest or with exercise) as well as to detail known risk factors 
for CVD (hypertension, hypercholesterolemia, diabetes 
mellitus, cigarette smoking, family history of CVD) and 
medication usage (aspirin, statins, antihypertensives, diabetic 
medication). Additionally, individuals were questioned 
regarding symptoms and signs suggestive of acute infection 
(fevers, cough, sputum production, etc).
Exclusion criteria included the presence of known heart 
disease (including previous myocardial infarction [MI]) or 
symptoms suggestive of cardiac disease, peripheral vascular 
disease, history of stroke or symptomatic cerebral ischemia 
as well as the presence of symptoms consistent with current 
infection. Furthermore, all those taking aspirin, statin and/or 
anti-hypertensive medications were excluded.
Cardiovascular risk assessment
Cardiovascular assessment was performed on all included 
study subjects and comprised complete physical examination 
and fasting phlebotomy. Cardiovascular risk was determined 
by use of both Framingham and SCORE calculation on all 
individuals.
Clinical examination
Physical examination was performed on all subjects 
and included sphygmomanometry (mmHg) along with 
measurement of waist circumference and body mass index 
(BMI) calculation (calculated as weight in kilograms divided 
by the square of height in meters; kg/m2).
Hematological and biochemical assessment
Early morning, blood samples for serum measurement of 
WBC with differential as well as glucose, total cholesterol, 
low-density lipoprotein cholesterol (LDL), high-density 
lipoprotein (HDL) and triglyceride levels were drawn from 
an antecubital vein of participants resting in a supine position 
after an overnight fasting period of a minimum of ten hours. 
Once drawn, all samples were put on ice and were processed 
within 30 minutes. Total and peripheral differential WBC 
counts (neutrophils, lymphocytes, monocytes and basophils) 
were performed using a Sysmex NE-8000 hematology 
analyzer (TOA Medical Electronics, Kobe, Japan). Intra-
assay and inter-assay coefﬁ  cients of variation were  10%. 
Enzymatic colorimetric methods using a Cobras Intgera 800 
analyser (Roche, Basle, Switzerland) were used to determine 
the concentrations of fasting cholesterol, triglycerides and 
glucose (sensitivity  0.003 mmol/l, 0.4 mmol/l, 0.03 mmol/l, 
respectively). Appropriate standardization of the assays was 
performed at time intervals throughout the study period in 
compliance with quality-control measures.
Framingham heart risk score and SCORE estimation
10-year risk of CHD (whether fatal or nonfatal) and fatal CVD 
(including both coronary and cerebrovascular deaths) was 
calculated for all patients on the basis of the Framingham Heart 
Risk Score (Wilson et al 1998) and SCORE project (Conroy 
et al 2003) formulae respectively. Both these estimations are 
widely used and well validated means of ascribing gender-
speciﬁ  c cardiovascular risk. The Framingham Risk Score, 
derived from the Framingham Heart Study Cohort, predicts 
gender-speciﬁ  c 10-year risk of CHD development by assigning 
a weighting to each individual’s age, sex, smoking status, total 
cholesterol, high-density lipoprotein cholesterol, systolic blood 
pressure, and the presence of diabetes. The European SCORE 
is a risk stratiﬁ  cation model developed by the European Society 
of Cardiology that allows direct estimation of 10-year risk of 
fatal CVD at any site for use in primary prevention programs. 
This means of risk stratiﬁ  cation again assigns numerical 
weighting to each individual’s age, sex, total cholesterol, 
systolic blood pressure, and smoking status.
Statistical analysis
Statistical analysis was performed using the SPSS Version 11 
(SPSS Inc 1989–2001, Chicago, Illinois, USA). Univariate 
regression models were ﬁ  t for each cardiovascular risk Vascular Health and Risk Management 2008:4(1) 179
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parameter to examine the independent relationships between 
differential WBC and cardiovascular risk parameters. 
Log transformation of variables was performed where 
appropriate to correct for skew (glucose, total cholesterol, 
HDL, LDL, and triglycerides). Subsequently, backward 
multiple linear regression models were ﬁ  tted in order to 
determine whether independent associations exist between 
differential WBC and cardiovascular risk, as quantiﬁ  ed by 
the Framingham and SCORE risk stratiﬁ  cation models. 
A relationship was considered statistically signiﬁ  cant if 
p   0.05.
Results
Of 1716 subjects (1026 men, 690 women) attending for 
screening over the 15-month study period, 333 were excluded 
by the criteria detailed above. Fifty one had either known 
heart disease or a history of cerebrovascular accident or had 
symptoms suggestive of cardiac disease, peripheral vascular 
disease, symptomatic cerebral ischemia or current infection 
and were thus excluded from further evaluation. A further 282 
were taking aspirin and/or a statin and/or anti-hypertensive 
medication on attendance. Therefore, the study group com-
prised 1383 participants (795 men, 588 women) who met the 
inclusion criteria. The baseline characteristics for our study 
population and the distribution of potential risk factors for 
CVD are displayed in Table 1.
Univariate regression models were ﬁ  tted in order to 
quantify the association between total and differential 
WBC counts and standard risk parameters for the develop-
ment of CVD (see Tables 2a and 2b). Signiﬁ  cant relation-
ships between total WBC count and risk parameters for 
cardiovascular disease development were demonstrated 
with WBC found to be signiﬁ  cantly related to BMI, waist 
circumference, systolic blood pressure, HDL cholesterol, 
and triglyceride levels. Additionally, total WBC count was 
associated with SCORE but not to Framingham risk estima-
tion. Of the leuckocyte subtypes, monocyte count showed the 
most compelling evidence of a signiﬁ  cant relationship with 
cardiovascular risk and risk factors. Signiﬁ  cant relationships 
were demonstrated between monocyte count and BMI, waist 
circumference, systolic blood pressure, HDL cholesterol and 
triglyceride concentrations. Furthermore, signiﬁ  cant relation-
ships between monocyte count and risk of CVD development 
using both Framingham and SCORE cardiovascular risk pre-
diction models were evident. Univariate regression models 
also showed neutrophil count to be signiﬁ  cantly associated 
with BMI, HDL cholesterol, and triglyceride measurements. 
Neutrophil count was, in addition, signiﬁ  cantly associated 
with overall risk of having a fatal cardiovascular event in the 
next ten years, as estimated by the SCORE cardiovascular 
risk prediction model. Eosinophil count demonstrated sig-
niﬁ  cant associations with BMI, waist circumference, HDL 
Table 1 Baseline characteristics and distribution of potential risk factors for CVD for the study population
Variable Female      Male   
Smoking status  Nonsmokers  Ex-smokers  Current smokers  Nonsmokers  Ex-smokers  Current smokers
n = 427  89  72  456  252  87
Age (yrs)  51 (±7.9) 50  (±7.5) 49  (±6.4) 56  (±5.1) 56  (±5.2) 56  (±5.6)
Waist circumference (cm)  80.90 (±11.5) 81.83  (±10.2) 81.58  (±10.1) 94.62  (±10.7) 95.92  (±10.2) 94.99  (±10.5)
BMI (kg/m2) 24.81  (±4.1) 25.35  (±3.4) 24.48  (±3.95) 27.01  (±3.4) 27.66  (±3.4) 27.28  (±3.37)
Systolic BP (mmHg)  119.48 (±17.8) 118.94  (±17.7) 117.21  (±14.6) 125.52  (±16.5) 128.5  (±16.5) 130.25  (±18.5)
Diastolic BP (mmHg)  76.83 (±10.3) 77.92  (±10.6) 76.28  (±10.08) 82.01  (±9.3) 86.73  (±5.19) 82.72  (±9.49)
WBC count (*109 cells/L)  6.05 (±1.52) 6.07  (±1.52) 7.21  (±1.97) 6.26  (±1.62) 6.34  (±1.60) 7.17  (±1.95)
Neutrophils (*109 cells/L)  4.63 (±1.23) 3.46  (±1.13) 4.36  (±1.51) 3.65  (±1.26) 3.68  (±1.07) 4.30  (±1.47)
Lymphocytes (*109 cells/L)  1.83 (±0.51) 1.91  (±0.61) 2.07  (±0.62) 1.81  (±0.57) 1.81  (±0.48) 2.02  (±0.62)
Basophils (*109 cells/L)  0.05 (±0.03) 0.05  (±0.02) 0.07  (±0.03) 0.06  (±0.04) 0.06  (±0.05) 0.07  (±0.03)
Monocytes (*109 cells/L)  0.34 (±0.15) 0.33  (±0.10) 0.37  (±0.11) 0.38  (±0.12) 0.40  (±0.12) 0.42  (±0.11)
Eosinophils (*109 cells/L)  0.17 (±0.11) 0.18  (±0.12) 0.20  (±0.03) 0.19  (±0.11) 0.22  (±0.15) 0.23  (±0.03)
Glucose (mmol/dl)  4.99 (±2.12) 5.48  (±4.4) 5.38  (±4.89) 5.10  (±0.63) 5.14  (±0.7) 5.20  (±1.08)
Triglycerides (mg/dl)  0.99 (±0.55) 1.08  (±0.67) 1.14  (±0.60) 1.43  (±0.99) 1.67  (±1.53) 1.71  (±0.84)
Total cholesterol (mg/dl)  5.74 (±0.96) 5.79  (±0.99) 5.74  (±0.99) 5.93  (±2.91) 5.91  (±1.01) 5.76  (±1.02)
HDL (mmol/dl)  1.91 (±0.45) 1.90  (±0.5) 1.87  (±0.48) 1.47  (±0.38) 1.47  (±0.33) 1.42  (±0.46)
LDL (mmol/dl)  3.25 (±0.90) 3.40  (±0.88) 3.35  (±0.90) 3.56  (±0.89) 3.70  (±0.89) 3.52  (±1.06)
Framingham risk score  3.64 (±2.7) 3.73  (±3.15) 3.85  (±2.76) 4.67  (±2.1) 4.90  (±1.96) 6.77  (±2.66)
SCORE 0.88  (±1.14) 0.98  (±1.24) 0.88  (±0.89) 3.53  (±2.56) 3.76  (±2.67) 7.24  (±6.44)
Note: Data are given as mean ± SEM value unless otherwise stated.
Abbreviations: BMI, body mass index; BP, blood pressure; WBC, white blood cell; HDL, high density lipoprotein; LDL, low density lipoprotein.Vascular Health and Risk Management 2008:4(1) 180
Waterhouse et al
T
a
b
l
e
 
2
 
S
t
a
t
i
s
t
i
c
a
l
 
a
n
a
l
y
s
i
s
 
u
s
i
n
g
 
u
n
i
v
a
r
i
a
t
e
 
r
e
g
r
e
s
s
i
o
n
 
m
o
d
e
l
s
 
t
o
 
e
x
a
m
i
n
e
 
t
h
e
 
r
e
l
a
t
i
o
n
s
h
i
p
 
b
e
t
w
e
e
n
 
t
o
t
a
l
 
a
n
d
 
d
i
f
f
e
r
e
n
t
i
a
l
 
W
B
C
 
c
o
u
n
t
s
 
a
n
d
 
t
h
e
 
f
o
l
l
o
w
i
n
g
 
c
a
r
d
i
o
v
a
s
c
u
l
a
r
 
r
i
s
k
 
p
a
r
a
m
e
t
e
r
s
 
(
a
)
 
F
r
a
m
i
n
g
h
a
m
 
a
n
d
 
S
C
O
R
E
 
r
i
s
k
 
e
s
t
i
m
a
t
e
s
,
 
B
M
I
,
 
w
a
i
s
t
 
c
i
r
c
u
m
f
e
r
e
n
c
e
,
 
a
n
d
 
s
y
s
t
o
l
i
c
 
B
P
;
 
(
b
)
 
T
o
t
a
l
 
c
h
o
l
e
s
t
e
r
o
l
,
 
L
D
L
,
 
H
D
L
,
 
a
n
d
 
t
r
i
g
l
y
c
e
r
i
d
e
s
(
a
)
L
e
u
k
o
c
y
t
e
 
c
o
u
n
t
 
F
r
a
m
i
n
g
h
a
m
 
 
S
C
O
R
E
 
 
 
B
M
I
 
(
k
g
/
m
2
)
 
 
W
a
i
s
t
 
c
i
r
c
u
m
f
e
r
e
n
c
e
 
(
c
m
)
 
S
y
s
t
o
l
i
c
 
B
P
 
(
m
m
H
g
)
 
β
 
S
E
 
p
 
β
 
S
E
 
p
 
β
 
S
E
 
p
 
β
 
S
E
 
p
 
β
 
S
E
 
p
T
o
t
a
l
 
W
B
C
 
c
o
u
n
t
 
0
.
0
5
4
 
0
.
0
4
2
 
0
.
1
9
6
 
0
.
1
2
9
 
0
.
0
5
2
 
0
.
0
1
3
 
0
.
3
6
5
 
0
.
0
6
4
 
 
0
.
0
0
0
5
 
1
.
5
1
8
 
0
.
2
8
3
 
 
0
.
0
0
0
5
 
0
.
5
7
0
 
0
.
2
9
1
 
0
.
0
5
M
o
n
o
c
y
t
e
s
 
1
.
0
9
1
 
0
.
5
2
2
 
0
.
0
3
7
 
3
.
0
9
5
 
0
.
6
3
3
 
 
0
.
0
0
0
5
 
5
.
2
1
4
 
0
.
7
8
5
 
 
0
.
0
0
0
5
 
2
1
.
8
6
6
 
2
.
5
9
6
 
 
0
.
0
0
0
5
 
1
0
.
7
3
8
 
3
.
5
7
6
 
0
.
0
0
3
N
e
u
t
r
o
p
h
i
l
s
 
0
.
0
8
5
 
0
.
0
5
4
 
0
.
1
1
6
 
0
.
1
7
5
 
0
.
0
6
6
 
0
.
0
0
8
 
0
.
3
3
 
0
.
8
3
 
 
0
.
0
0
0
5
 
−
0
.
0
1
6
 
0
.
3
8
 
0
.
6
8
1
 
0
.
5
9
0
 
0
.
3
7
3
 
0
.
1
1
4
L
y
m
p
h
o
c
y
t
e
s
 
0
.
0
1
5
 
0
.
1
2
5
 
0
.
9
0
4
 
−
0
.
0
5
2
 
0
.
1
5
3
 
0
.
7
3
0
 
0
.
9
0
8
 
0
.
1
9
 
 
0
.
0
0
0
5
 
2
.
5
5
9
 
0
.
6
3
6
 
 
0
.
0
0
0
5
 
1
.
6
0
3
 
0
.
8
5
7
 
0
.
0
6
2
E
o
s
i
n
o
p
h
i
l
s
 
0
.
1
0
4
 
0
.
5
4
8
 
0
.
8
4
9
 
1
.
8
8
3
 
0
.
6
6
8
 
0
.
0
0
5
 
2
.
4
6
1
 
0
.
8
3
4
 
0
.
0
0
3
 
0
.
1
3
7
2
 
2
.
7
7
6
 
 
0
.
0
0
0
5
 
1
.
7
3
4
 
3
.
7
6
2
 
0
.
6
4
5
B
a
s
o
p
h
i
l
s
 
1
.
9
8
7
 
1
.
8
5
9
 
0
.
2
8
5
 
7
.
5
8
2
 
2
.
2
6
2
 
0
.
0
0
1
 
1
0
.
5
5
2
 
2
.
8
2
 
 
0
.
0
0
0
5
 
3
8
.
1
4
2
 
9
.
4
1
7
 
 
0
.
0
0
0
5
 
2
7
.
3
6
3
 
1
2
.
7
3
6
 
0
.
0
3
2
(
b
)
L
e
u
k
o
c
y
t
e
 
c
o
u
n
t
 
T
o
t
a
l
 
c
h
o
l
e
s
t
e
r
o
l
 
(
m
g
/
d
l
)
 
H
D
L
 
(
m
m
o
l
/
d
l
)
 
 
L
D
L
 
(
m
m
o
l
/
d
l
)
 
 
T
r
i
g
l
y
c
e
r
i
d
e
s
 
(
m
g
/
d
l
)
 
β
 
S
E
 
p
 
β
 
S
E
 
p
 
β
 
S
E
 
p
 
β
 
S
E
 
p
T
o
t
a
l
 
W
B
C
 
c
o
u
n
t
 
0
.
0
0
9
 
0
.
0
1
6
 
0
.
5
6
8
 
−
0
.
0
4
8
 
0
.
0
0
8
 
 
0
.
0
0
0
5
 
0
.
0
1
6
 
0
.
0
1
5
 
0
.
2
8
9
 
0
.
0
9
1
 
0
.
0
1
7
 
 
0
.
0
0
0
5
M
o
n
o
c
y
t
e
s
 
−
0
.
2
0
8
 
0
.
2
0
3
 
0
.
1
6
8
 
−
0
.
6
3
9
 
0
.
0
9
4
 
 
0
.
0
0
0
5
 
−
0
.
1
1
0
 
0
.
1
8
8
 
0
.
5
5
9
 
0
.
7
8
7
 
0
.
2
0
5
 
 
0
.
0
0
0
5
N
e
u
t
r
o
p
h
i
l
s
 
−
0
.
0
0
5
 
0
.
0
2
1
 
0
.
7
8
8
 
−
0
.
0
4
9
 
0
.
0
1
 
 
0
.
0
0
0
5
 
0
.
0
0
9
 
0
.
0
2
 
0
.
6
4
5
 
0
.
0
9
1
 
0
.
0
2
1
 
 
0
.
0
0
0
5
L
y
m
p
h
o
c
y
t
e
s
 
0
.
1
4
1
 
0
.
0
4
8
 
0
.
0
0
4
 
−
0
.
0
8
2
 
0
.
0
2
3
 
 
0
.
0
0
0
5
 
0
.
0
9
1
 
0
.
0
4
5
 
0
.
0
4
2
 
0
.
2
2
2
 
0
.
0
4
9
 
 
0
.
0
0
0
5
E
o
s
i
n
o
p
h
i
l
s
 
−
0
.
0
0
5
 
0
.
2
1
3
 
0
.
7
8
5
 
−
0
.
2
5
1
 
0
.
1
0
0
 
0
.
0
0
5
 
−
0
.
0
2
8
 
0
.
1
9
8
 
0
.
8
8
4
 
0
.
4
3
0
 
0
.
2
1
6
 
0
.
0
4
6
B
a
s
o
p
h
i
l
s
 
0
.
4
3
4
 
0
.
7
2
2
 
0
.
5
4
7
 
−
0
.
8
9
8
 
0
.
3
4
0
 
0
.
0
0
8
 
0
.
4
3
7
 
0
.
6
7
0
 
0
.
5
1
4
 
2
.
4
4
9
 
0
.
7
3
0
 
0
.
0
0
1
N
o
t
e
:
 
*
S
i
g
n
i
ﬁ
 
c
a
n
t
 
r
e
l
a
t
i
o
n
s
h
i
p
 
i
e
,
 
p
 
 
 
0
.
0
5
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
B
M
I
,
 
b
o
d
y
 
m
a
s
s
 
i
n
d
e
x
;
 
B
P
,
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
;
 
β
,
 
r
e
g
r
e
s
s
i
o
n
 
c
o
e
f
ﬁ
 
c
i
e
n
t
;
 
H
D
L
,
 
h
i
g
h
-
d
e
n
s
i
t
y
 
l
i
p
o
p
r
o
t
e
i
n
;
 
L
D
L
,
 
l
o
w
-
d
e
n
s
i
t
y
 
l
i
p
o
p
r
o
t
e
i
n
;
 
S
E
,
 
s
t
a
n
d
a
r
d
 
e
r
r
o
r
 
o
f
 
t
h
e
 
m
e
a
n
;
 
W
B
C
,
 
w
h
i
t
e
 
b
l
o
o
d
 
c
e
l
l
.Vascular Health and Risk Management 2008:4(1) 181
Cardiovascular risk and monocyte count
cholesterol, and triglyceride concentrations as well as with 10 
year risk of having a fatal cardiovascular event, as described 
by SCORE. Basophil count was signiﬁ  cantly associated with 
BMI, waist circumference, systolic blood pressure, HDL 
cholesterol, and triglyceride concentrations as well as with 
SCORE-estimated risk. Lymphocyte count demonstrated 
signiﬁ  cant associations with BMI, waist circumference, 
total cholesterol, HDL cholesterol, LDL cholesterol, and 
triglyceride concentrations. However, despite the signiﬁ  cant 
statistical signiﬁ  cance of the relationship between lympho-
cyte count and risk parameters for CVD development, the 
association did not translate into associated increased 10 
year risk of either CVD development or risk of having a fatal 
cardiovascular event.
On backward stepwise linear regression model analysis, 
monocyte count was the only WBC component found to be 
independently associated with both Framingham and SCORE 
cardiovascular risk stratiﬁ  cation models (see Table 3a). 
While lymphocyte and basophil counts were also shown by 
this means to be independently associated with SCORE (see 
Table 3b), the relationship is not as compelling. Therefore, 
having demonstrated monocyte count to be an independent 
predictor of future cardiovascular risk, plots showing median 
monocyte count versus individual components of the FRS 
and SCORE were constructed (Figures 1–5). Furthermore, 
Figure 6 demonstrates the monocyte level increment with 
increasing calculated Framingham and SCORE coronary 
risk categories. The beta co-efﬁ  cient already calculated 
by the multivariate analyses indicated that an increment of 
monocyte count by 0.057 and 0.128 was associated with a 
1% increase in Framingham and SCORE risk estimation, 
respectively.
Finally, the predictive ability of monocyte count was 
compared to that of BMI and waist circumference for the 
strength of an association with both Framingham and SCORE 
predictive risk of cardiovascular events (see Table 4). Addi-
tional parameters such as LDL, smoking status, age, and 
systolic blood pressure were not examined in this fashion as 
they themselves are components of both scores. Thus it can 
be appreciated that, while monocyte count is a predictor of 
future cardiovascular events, its predictive ability is exceeded 
by both BMI and waist circumference.
Discussion
WBC count provides a widely available and rapidly per-
formed means of assessing systemic inﬂ  ammatory status 
that is both well-standardized and inexpensive (Hoffman 
et al 2004). However despite prior studies showing WBC 
count to be an independent risk factor and prognostic indi-
cator of future cardiovascular outcome that may hold true 
regardless of actual current clinical CVD status (Prentice 
et al 1982a; Zalokar 1983; Kannel et al 1992; Weiss et al 
1995; Danesh et al 1998; James et al 1999; Lee et al 2001; 
Barron et al 2001; Haim et al 2004; Gillum et al 2005; 
Margolis et al 2005; Roy et al 2006), the exact clinical 
relevance of the association remains to be fully elucidated 
(Madjid et al 2004). Of WBC sub-fractions, neutrophil 
counts have, to date, shown the strongest association with 
CVD incidence and mortality (Prentice et al 1982b; Zalokar 
1983; Olivares et al 1993; Kirtane et al 2004; Wheeler et al 
2004; Margolis et al 2005; Gillum et al 2005) although the 
majority of studies have concentrated on either patients 
with acute symptoms or on those at highest risk of overt 
CVD. Recent ﬁ  ndings that neutrophil/lymphocyte ratio 
provides the greatest risk prediction in patients undergoing 
angiographic studies for suspected CHD symptoms seem 
to conﬁ  rm that this subtype (like C-reactive protein [CRP]) 
may represent either an adaptive or maladaptive response 
of reparative intent towards atherosclerotic plaque rupture 
and clinical signiﬁ  cant ischemia (Horne et al 2005; Dragu 
et al 2006). Little information however is available con-
cerning the independent predictive ability of speciﬁ  c WBC 
subtypes to predict CVD risk, independent of standard risk 
Table 3 Statistical analysis using multivariable linear regression 
modeling to determine whether independent associations exist 
between (a) differential white cell count and Framingham Risk and 
(b) differential white cell count and SCORE. Variables entered into 
the stepwise regression model comprise total white cell count, 
neutrophils, lymphocytes, basophils, monocytes and eosinophils
(a)
Multivariable linear regression modeling examining for inde-
pendent associations between differential white cell count and 
Framingham risk estimation.
WBC subtype  β Standard  error  p  value
Monocytes 0.057  2.12  0.03
(b)
Multivariable linear regression modeling examining for inde-
pendent associations between differential white cell count and 
SCORE risk estimation.
WBC subtype  β Standard  error  p  value
Monocytes 0.128  4.436   0.0005
Lymphocytes  −0.082  −2.807 0.005
Basophils 0.067  2.366  0.02
Abbreviations: β, regression coefﬁ  cient; Standard Error, standard error of regres-
sion coefﬁ  cient; WBC, white blood cells.Vascular Health and Risk Management 2008:4(1) 182
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factors, in individuals without overt symptoms of cardiac 
disease.
This prospective cohort study in an asymptomatic popula-
tion demonstrates that, of all WBC subtypes, the most signiﬁ  -
cant relationship with established risk parameters for CVD 
development exists for monocyte count and that, furthermore, 
this subfraction alone was independently associated with 
both Framingham and SCORE risk estimation. Monocyte-
macrophages are central mediators in the pathogenesis of 
atherosclerosis in both the coronary and peripheral arterial 
circulations (Libby 2002; Hansson 2005). Circulating mono-
cytes become recruited to atherogenic foci where, through 
Figure 1 Composite ﬁ  gure showing relationship of median monocyte count to patient variables of (a) Age; (b) Systolic blood pressure; (c) Total cholesterol; (d) HDL choles-
terol; and (e) LDL cholesterol as well as with (f) Framingham and (g) SCORE risk estimates.
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
(a)( b)
(c) (d) (e)
(f) (g)Vascular Health and Risk Management 2008:4(1) 183
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Figure 2 Comparison of median monocyte count and total cholesterol.
Figure 3 Comparison of median monocyte count and LDL cholesterol.
Abbreviation: LDL, low-density lipoprotein.Vascular Health and Risk Management 2008:4(1) 184
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Figure 4 Comparison of median monocyte count and HDL cholesterol.
Abbreviation: HDL, high-density lipoprotein.
Figure 5 Comparison of median monocyte count and age.Vascular Health and Risk Management 2008:4(1) 185
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(a)
(b)
Figure 6 Comparison of (a) Framingham and (b) SCORE risk estimates with monocyte count (*109 cells/L).
(a)
(b)Vascular Health and Risk Management 2008:4(1) 186
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differentiation into macrophages, they establish a persistent 
cellular reaction that underlies disease progression. However, 
more crucial may be their association with atherosclerotic 
plaque instability and rupture- the precedent events of arterial 
thrombosis and occlusion that portend clinically signiﬁ  cant 
ischemia (Falk 2006). Although it is somewhat surprising that 
few studies to date have directly assessed the association of 
circulating monocytes levels with clinically relevant cardio-
vascular end-points, the ﬁ  ndings of this study are supported 
by the conclusions of Nasir and colleagues (2005) who also 
determined a signiﬁ  cant association between monocyte count 
and atherosclerotic disease in patients without known cardio-
vascular disease albeit in the peripheral arterial circulation. 
Furthermore, our ﬁ  ndings are particularly intriguing given 
the recent demonstration by Swirski and colleagues (2007) 
that certain monocyte subsets dominate hypercholesterol-
emia-associated monocytosis and give rise speciﬁ  cally to 
macrophages in atheromata. Finally, the utility of this WBC 
subtype in risk assessment seems particularly appealing 
given that it less inherently susceptible to ﬂ  uctuations due 
to superimposed acute inﬂ  ammatory conditions or infections 
than are overall WBC or neutrophil subfractions or indeed 
other acute phase reactants such as CRP.
As does any clinical investigation, however, this prospec-
tive, observational study has potential limitations. Although 
a single WBC measurement was found to be signiﬁ  cantly 
associated with currently utilized estimates of future cardio-
vascular risk; multiple measurements over time and changes 
in those measurements may provide a more accurate mecha-
nism for predicting future CVD and mortality. If this is so 
however, the association found by this study would represent 
an underestimation of the actual relationship between mono-
cyte count and CVD, and, thus, our conclusions may in fact 
be conservative. Additionally, the Framingham Heart Study 
may not apply to countries with low risk of heart disease, and 
there has been some concern over its use when applied to the 
diabetic population, tending to underestimate an individual’s 
probability of progressing to CHD (McEwan et al 2004). 
However, despite evidence that risk estimates based on Fram-
ingham generalize well to the population of the Republic of 
Ireland (Haq et al 1999), and is thus applicable to our study 
population, there is concern that this risk estimate (and indeed 
others) (Empana et al 2003) may overestimate absolute risk 
in European populations (Menotti et al 2000; Pyorala 2000; 
Thomsen et al 2002; Hense et al 2003). Therefore, to ensure 
an accurate and reliable estimate of absolute CVD risk in our 
study population, we additionally stratiﬁ  ed each participant 
according to SCORE criteria, a risk stratiﬁ  cation model that 
has speciﬁ  cally validated in European countries with similar 
levels of risk as Ireland and previously shown to be useful 
in ascribing risk in asymptomatic populations similar to our 
own (Aktas et al 2004). Although the validity of such scores 
has been questioned by some (Topol and Lauer 2003), they 
have nonetheless been integrated into primary cardiovascular 
disease prevention guidelines.
The ﬁ  ndings of this study therefore suggest that monocyte 
count, a simple inexpensive test, may provide important risk 
information to aid prediction of future CVD development 
in disease free adults and so may help guide therapeutic 
intervention aimed at its interruption.
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